Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 264


Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.

Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V.

Oncotarget. 2016 Mar 15;7(11):11817-37. doi: 10.18632/oncotarget.7857.


Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation.

Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V.

Cell Death Differ. 2016 Mar;23(3):509-20. doi: 10.1038/cdd.2015.119. Epub 2015 Sep 11.


Battery related cobalt and REE flows in WEEE treatment.

Sommer P, Rotter VS, Ueberschaar M.

Waste Manag. 2015 Nov;45:298-305. doi: 10.1016/j.wasman.2015.05.009. Epub 2015 Jun 6.


p53 in liver pathologies-taking the good with the bad.

Charni M, Rivlin N, Molchadsky A, Aloni-Grinstein R, Rotter V.

J Mol Med (Berl). 2014 Dec;92(12):1229-34. doi: 10.1007/s00109-014-1223-5. Epub 2014 Nov 19. Review.


Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.

Solomon H, Sharon M, Rotter V.

Cell Death Differ. 2014 Sep;21(9):1347-9. doi: 10.1038/cdd.2014.99. No abstract available.


Endothelial matrix assembly during capillary morphogenesis: insights from chimeric TagRFP-fibronectin matrix.

Chang F, Lemmon CA, Nilaratanakul V, Rotter V, Romer L.

J Histochem Cytochem. 2014 Nov;62(11):774-90. doi: 10.1369/0022155414547419. Epub 2014 Jul 25.


Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, Rotter V, Liu B, El-Naggar AK, Donehower LA, Martinez LA, Lozano G.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11145-50. doi: 10.1073/pnas.1404139111. Epub 2014 Jul 14.


The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.

Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, Pe'er D, Radlwimmer B, Lichter P, Rotter V, Aloni-Grinstein R.

Cell Death Differ. 2014 Sep;21(9):1419-31. doi: 10.1038/cdd.2014.57. Epub 2014 May 16.


Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.

Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, Geiger T.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):7006-11. doi: 10.1073/pnas.1320428111. Epub 2014 Apr 28.


The paradigm of mutant p53-expressing cancer stem cells and drug resistance.

Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S, Rotter V.

Carcinogenesis. 2014 Jun;35(6):1196-208. doi: 10.1093/carcin/bgu073. Epub 2014 Mar 21. Review.


The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells.

Leibovich-Rivkin T, Liubomirski Y, Meshel T, Abashidze A, Brisker D, Solomon H, Rotter V, Weil M, Ben-Baruch A.

BMC Cancer. 2014 Mar 6;14:158. doi: 10.1186/1471-2407-14-158.


p53: the barrier to cancer stem cell formation.

Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V.

FEBS Lett. 2014 Aug 19;588(16):2580-9. doi: 10.1016/j.febslet.2014.02.011. Epub 2014 Feb 19.


p53 orchestrates between normal differentiation and cancer.

Rivlin N, Koifman G, Rotter V.

Semin Cancer Biol. 2015 Jun;32:10-7. doi: 10.1016/j.semcancer.2013.12.006. Epub 2014 Jan 7. Review.


p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production.

Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V.

Cancer Metab. 2013 Feb 4;1(1):9. doi: 10.1186/2049-3002-1-9.


Data availability and the need for research to localize, quantify and recycle critical metals in information technology, telecommunication and consumer equipment.

Chancerel P, Rotter VS, Ueberschaar M, Marwede M, Nissen NF, Lang KD.

Waste Manag Res. 2013 Oct;31(10 Suppl):3-16. doi: 10.1177/0734242X13499814.


'Cancer associated fibroblasts'--more than meets the eye.

Madar S, Goldstein I, Rotter V.

Trends Mol Med. 2013 Aug;19(8):447-53. doi: 10.1016/j.molmed.2013.05.004. Epub 2013 Jun 13. Review.


Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M.

Cancer Cell. 2013 May 13;23(5):634-46. doi: 10.1016/j.ccr.2013.03.022. Erratum in: Cancer Cell. 2013 Aug 12;24(2):272. Rozenfeld, Nitzan [corrected to Rosenfeld, Nitzan].


p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model.

Olsen JR, Oyan AM, Rostad K, Hellem MR, Liu J, Li L, Micklem DR, Haugen H, Lorens JB, Rotter V, Ke XS, Lin B, Kalland KH.

PLoS One. 2013 May 1;8(5):e62547. doi: 10.1371/journal.pone.0062547. Print 2013.


Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.

Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V.

PLoS One. 2013 Apr 22;8(4):e61353. doi: 10.1371/journal.pone.0061353. Print 2013.


p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity.

Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V.

Cell Death Differ. 2013 May;20(5):774-83. doi: 10.1038/cdd.2013.9. Epub 2013 Feb 15.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk